<DOC>
	<DOCNO>NCT02508636</DOCNO>
	<brief_summary>This phase II study evaluate efficacy , safety , toxicity , feasibility addition enzalutamide leuprolide total duration 24 month patient high-risk prostate cancer pelvic node positive disease receive radiotherapy . Very high-risk prostate cancer define 2 follow characteristic : 1 ) cT3a/b , 2 ) PSA ≥20 &lt; 150 , 3 ) Gleason 8-10 , 4 ) ≥33 % core involvement .</brief_summary>
	<brief_title>Trial Radiotherapy With Leuprolide Enzalutamide High Risk Prostate</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . Histologically confirm diagnosis adenocarcinoma prostate within 180 day prior registration high risk recurrence determine 2 follow combination : cT3a/b PSA ≥20 Gleason score 810 ≥33 % core involvement OR patient pelvic lymph node involvement ≥1cm determine pelvic CT MRI image meet eligibility criterion enrollment . 2 . Standard stag exams patient highrisk prostate cancer include bone scan NaF PET/CT scan , pelvic prostate MRI . 3 . No distant metastasis ( M0 ) bone scan NaF PET/CT within 90 day prior registration . Equivocal bone scan finding allow physician determines distant metastasis unlikely base clinical judgment . 4 . Zubrod Performance Status 02 within 60 day prior enrollment . 5 . Age ≥18 6 . Complete blood count ( CBC ) differential obtain within 30 day prior registration study , adequate bone marrow function define follow : 1 . Absolute neutrophil count ( ANC ) ≥1,800 cells/mm3 2 . Platelets ≥100,000 cells/mm3 3 . Hemoglobin ≥8.0 g/dl ( The use transfusion intervention achieve Hgb ≥ 8.0 g/dl acceptable ) 4 . Serum creatinine &lt; 2.0 mg/dl creatinine clearance &gt; 40 mL/min within 30 day prior registration 5 . Bilirubin &lt; 1.5 x ULN Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) &lt; 2 × ULN within 21 day prior registration 7 . Patients , even surgically sterilize ( i.e. , status post vasectomy ) , : 1 . Agree practice effective barrier contraception entire study treatment period 4 month ( 120 day ) last dose study drug , 2 . Agree completely abstain intercourse 8 . Patient must able provide studyspecific inform consent prior study entry . 1 . Definite evidence metastatic disease 2 . Prior radical prostatectomy bilateral orchiectomy reason 3 . Prior invasive malignancy ( except nonmelanoma skin cancer ) unless diseasefree require systemic therapy minimum 3 year . 4 . Prior systemic chemotherapy prostate cancer ( Note prior chemotherapy different cancer allow ) . 5 . Prior radiotherapy , include brachytherapy , region prostate would result overlap radiation therapy field . 6 . Previous hormonal therapy LHRH agonist ( e.g . goserelin , leuprolide ) , antiandrogens ( e.g . flutamide , bicalutamide ) , estrogens ( e.g . DES ) , surgical castration ( orchiectomy ) 7 . Known hypersensitivity enzalutamide related compound 8 . History adrenal insufficiency 9 . Patients sexually active willing/able use medically acceptable form contraception ; exclusion necessary treatment involve study may significantly teratogenic . 10 . Prior allergic reaction drug involve protocol . 11 . Cushing 's syndrome 12 . Severe chronic renal disease ( serum creatinine &gt; 2.0 mg/dl confirm creatinine clearance &lt; 40 mL/minute ) 13 . Chronic liver disease ( bilirubin &gt; 1.5x ULN , ALT AST &gt; 2x ULN ) 14 . Active/Uncontrolled Viral Hepatitis 15 . Chronic treatment glucocorticoid within one year . 16 . History seizure include febrile seizure condition may predispose seizure ( e.g. , prior stroke , brain arteriovenous malformation , head trauma loss consciousness require hospitalization ) . Also , current prior treatment antiepileptic medication treatment seizures history loss consciousness transient ischemic attack within 12 month prior randomization . 17 . Clinically significant cardiovascular disease include : 1 . Myocardial infarction within 6 month prior screen 2 . Uncontrolled angina within 3 month prior screen 3 . Congestive heart failure New York Heart Association ( NYHA ) class 3 4 , subject history congestive heart failure NYHA class 3 4 past , unless screen echocardiogram multigated acquisition ( MUGA ) scan perform within 3 month result leave ventricular ejection fraction ≥45 % ; 4 . History clinically significant ventricular arrhythmia ( e.g . ventricular tachycardia , ventricular fibrillation , torsades de pointes ) ; 5 . History Mobitz II second degree third degree heart block without permanent pacemaker place ; 6 . Uncontrolled hypertension indicate rest systolic blood pressure &gt; 170 mm Hg diastolic blood pressure &gt; 105 mm Hg screening . Patients initially elevate systolic blood pressure &gt; 170 mm Hg diastolic blood pressure &gt; 105 mm Hg eligible undergo medical management rescreened .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>